CDMO Ajinomoto forges ahead with Forge Biologics in $620M acquisition
When the FDA last month rejected Outlook Therapeutics' application for a reformulated version of Roche’s cancer drug Avastin, the agency pointed to issues with the drug’s manufacturing process in a complete response letter (CRL).
Aji Bio-Pharma, DNDi to develop treatment for cutaneous leishmaniasis infections
Immunotherapy-focused HiFiBiO Therapeutics raised $67 million in series C. Kyowa Kirin won an FDA go-ahead for Parkinson's add-on therapy Nourianz. A probe at India's securities agency reportedly cleared Sun Pharma of alleged violations.
Ajinomoto Bio-Pharma Services has concluded a process that will allow the CDMO to operate in the gene therapy space. The company has fully integrated oligonucleotides producer GeneDesign into its operations.
Ajinomoto Bio-Pharma Services, a global provider of bio-pharmaceutical contract development and manufacturing services, has appointed Jean-Baptiste Agnus as vice president of sales and marketing. Mr. Agnus brings extensive leadership, business development, and sales experience in the bio-pharmaceutical contract development and manufacturing industry